Radiation

New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

Retrieved on: 
Monday, April 22, 2024
Oncology, Data Management, Health, Technology, Health Technology, Software, Biotechnology, Radiation, Patient, Prostate, Risk, Safety, JCO, MVA, Prostate cancer, Disease, Urology, Intelligence, Neoplasm, Biomarker, Waiting, GRID, Medical imaging

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance (AS) for prostate cancer, the Decipher Prostate Genomic Classifier is prognostic for identifying those whose disease is likely to progress.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance (AS) for prostate cancer, the Decipher Prostate Genomic Classifier is prognostic for identifying those whose disease is likely to progress.
  • The findings make the Decipher test the only gene expression test to have treatment-outcome data from a prospective, multi-center, phase 2, randomized trial in the AS population.
  • “The findings from the ENACT trial analysis demonstrate that the Decipher Prostate test is a predictor of disease progression on AS,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology.
  • The findings also demonstrated the use of Decipher GRID (Genomic Resource for Intelligent Discovery) as a research tool to help advance scientific understanding of prostate cancer.

Momentus and Ascent Solar Technologies Partner to Bring to Market Leading-Edge Solar Arrays

Retrieved on: 
Wednesday, April 17, 2024
Technology, Engineering, Satellite, Other Technology, Aerospace, Manufacturing, Alternative Energy, Energy, Machinery, Titan, Radiation, ASTI, Ascent, Partnership, Orbit, CIGS, Inc., Growth, Renewable energy

Momentus Inc. (NASDAQ: MNTS) (“Momentus”) and Ascent Solar Technologies (Nasdaq: ASTI) (“ASTI”) today announced a new partnership to jointly market leading-edge solar arrays utilizing the low-cost Tape Spring Solar Array (TASSA) being developed by Momentus and the high performance of Ascent’s flexible, lightweight photovoltaic modules.

Key Points: 
  • Momentus Inc. (NASDAQ: MNTS) (“Momentus”) and Ascent Solar Technologies (Nasdaq: ASTI) (“ASTI”) today announced a new partnership to jointly market leading-edge solar arrays utilizing the low-cost Tape Spring Solar Array (TASSA) being developed by Momentus and the high performance of Ascent’s flexible, lightweight photovoltaic modules.
  • The rapid growth in the production and deployment of thousands of satellites in space has led to the burgeoning need for low-cost, reliable solar arrays with high performance.
  • Momentus and Ascent are excited to partner to market a leading-edge solar array designed to provide key advantages to customers, such as low-cost, resiliency with less degradation in the harsh environment in space, flexibility, and the ability to efficiently generate large amounts of power.
  • Last year’s pathfinder TASSA demonstration validated solar blankets from Ascent Solar Technologies (Nasdaq: ASTI) (“ASTI”) as a mass efficient and robust power generation solution.

IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

Retrieved on: 
Tuesday, April 16, 2024
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Warning, Administration, Creatinine, Pneumonitis, Radiation, Prednisone, Patient, Incidence, Infection

Results showed 15.4% of patients experienced treatment-related serious adverse events with IMFINZI plus chemotherapy versus 17.3% with chemotherapy alone.

Key Points: 
  • Results showed 15.4% of patients experienced treatment-related serious adverse events with IMFINZI plus chemotherapy versus 17.3% with chemotherapy alone.
  • Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.
  • IMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
  • The primary endpoint is overall survival and key secondary endpoints included progression-free survival, objective response rate and safety.

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

Retrieved on: 
Tuesday, April 16, 2024
Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, Radiation, CMS, Pharmacy, Refrigeration, Hospital, Pembrolizumab, Cisplatin, Aplastic anemia, Mesothelioma, Disease, Restrictive lung disease, Pemetrexed, Patient, Medicare, Kidney, ALK, Medication, Amneal Pharmaceuticals, RTU, Pharmaceutical industry

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the launch of PEMRYDI RTU®, the first and only ready-to-use presentation of pemetrexed for injection.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the launch of PEMRYDI RTU®, the first and only ready-to-use presentation of pemetrexed for injection.
  • This product does not require reconstitution, dilution, or refrigeration, which is different than other versions of pemetrexed for injection.
  • “The launch of PEMRYDI RTU highlights Amneal’s deep commitment to oncology as we invest to develop injectable products that are important to healthcare providers and patients,” said Sean McGowan, Vice President, Biosimilars and Branded Oncology.
  • PEMRYDI RTU® injectable is available in two vial sizes: 100mg/10mL and 500 mg/50mL.

Fonon Highlights Applications for Its Laser Cutting Technology in Construction

Retrieved on: 
Monday, April 15, 2024
Technology, Retail, Manufacturing, Other Construction & Property, Home Goods, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Machine Tools, Metalworking & Metallurgy, Other Science, Other Technology, Science, Other Manufacturing, Steel, Titan, Radiation, Construction, Corporation, CNC, Metal, Alloy, FX, 3D printing

Fonon Corporation , a multi-market holding company, R&D center, equipment designer and manufacturer of advanced laser material processing systems for subtractive and additive manufacturing, highlights applications for its Titan FX laser cutting technologies in the construction industry.

Key Points: 
  • Fonon Corporation , a multi-market holding company, R&D center, equipment designer and manufacturer of advanced laser material processing systems for subtractive and additive manufacturing, highlights applications for its Titan FX laser cutting technologies in the construction industry.
  • In construction project management and execution, where every penny counts, laser cutting machines are an investment in precision and efficiency.
  • Fonon’s precision metal cutting solution, the Titan FX Laser Cutting System, is a game changer for the construction industry.
  • For more information about Fonon Corporation's laser cutting technology, please visit https://www.fonon.com .

QT Imaging’s Breast Acoustic CT™ Scanner to be Offered at The Center for New Medicine to Advance Personalized Prevention and Detection of Breast Cancer

Retrieved on: 
Thursday, April 11, 2024
Oncology, Medical Devices, Health, Consumer, Women, Biotechnology, FDA, Radiation, Woman, Internal medicine, Breast, Partnership, Research, 3D, Patient, Medicine, Medical director, Breast cancer, Medical imaging

The Center for New Medicine is one of the largest integrative medical clinics in North America, providing a personalized approach to health care including cancer prevention, its early detection, and internal medicine.

Key Points: 
  • The Center for New Medicine is one of the largest integrative medical clinics in North America, providing a personalized approach to health care including cancer prevention, its early detection, and internal medicine.
  • With the incorporation of the QT Imaging Breast Acoustic CT™ Scanner, the Center for New Medicine will expand their innovative services in women’s and breast health.
  • There is tremendous opportunity for new technology to advance women’s health, especially in breast cancer detection and treatment.
  • QT Imaging Breast Acoustic CT™ Scanner is the only 3D imaging device to receive FDA clearance for use as a transmission and reflection low frequency soundwaves imaging system for a patient’s breast.

Checkpoint Therapeutics, Inc. Stockholder Alert: Robbins LLP Reminds Investors of the CKPT Class Action

Retrieved on: 
Thursday, April 11, 2024
Class Action Lawsuit, Professional Services, Legal, FDA, BLA, Radiation, CMO, LLP, Patient, Checkpoint, Acquisition, News, Person, CKPT, Pharmaceutical industry

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) securities between March 10, 2021 and December 15, 2023.

Key Points: 
  • Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) securities between March 10, 2021 and December 15, 2023.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines

Retrieved on: 
Thursday, April 11, 2024
Research, Medical Devices, Hospitals, FDA, Genetics, Radiology, Health, Science, Oncology, Other Science, Blueprint, Woman, AGO, Breast, MD, Doctor of Philosophy, Pathology, Clinic, Gynaecology, Patient, Physician, Diagnosis, Standard of care, Radiation, Neoplasm, Breast cancer, Medical imaging

Agendia®, Inc. announced today that the company’s 80-gene molecular subtyping assay, BluePrint®, is now included in the latest version of German Gynecological Oncology Group (AGO) guidelines.

Key Points: 
  • Agendia®, Inc. announced today that the company’s 80-gene molecular subtyping assay, BluePrint®, is now included in the latest version of German Gynecological Oncology Group (AGO) guidelines.
  • Agendia’s MammaPrint® was added to the AGO guidelines in 2017, with level 1B medical evidence for identification of patient subgroups who can potentially forgo chemotherapy for breast cancer.
  • MammaPrint was also added to the list of prognostic and predictive factors for extended endocrine therapy in the 2023 AGO guidelines.
  • AGO is a joint expert group consisting of gynecological oncologists specialized in breast cancer and interdisciplinary members specialized in pathology, radiologic diagnostics, medical oncology and radiation oncology.

ENA Featuring New FBI Educational Series on Weapons of Mass Destruction

Retrieved on: 
Thursday, April 25, 2024
Trigger, Radiation, Mass, BSN, WMD, FBI, Death, Weapon of mass destruction, Emergency Nurses Association, Life, Weapon, Patient, Bureau, RN, USC, ENA, Alphabet song, Radioactive decay, MBA, Nursing

SCHAUMBURG, Ill., April 25, 2024 /PRNewswire/ -- With a goal to better inform health care workers about weapons of mass destruction, the Emergency Nurses Association and FBI recently partnered to launch the Bureau's "ABCs on WMDs" podcast series on the association's website.

Key Points: 
  • SCHAUMBURG, Ill., April 25, 2024 /PRNewswire/ -- With a goal to better inform health care workers about weapons of mass destruction, the Emergency Nurses Association and FBI recently partnered to launch the Bureau's "ABCs on WMDs" podcast series on the association's website.
  • ENA and the FBI recently partnered to launch the Bureau's "ABCs on WMDs" podcast series on the association's website.
  • The series is designed to educate emergency nurses – and the entire health care community – on how to better prepare for, mitigate and respond to WMD-related threats and incidents.
  • "The FBI appreciates the opportunity to partner with the Emergency Nurses Association to deliver a valuable training series" said Assistant Director of the FBI's Weapons of Mass Destruction Directorate Susan Ferensic.

Provisio Medical Announces FDA Clearance of the Provisio SLT IVUS™ System

Retrieved on: 
Thursday, April 25, 2024
SLT, FDA, Radiation, Blood, MD, Workflow, Moyamoya disease, Patient, Acquisition, Agent handling, SAN, Medical imaging

SAN DIEGO, April 25, 2024 /PRNewswire/ -- Provisio Medical today announced FDA 510(k) clearance of the Provisio™ SLT IVUS™ System. Sonic Lumen Tomography (SLT) technology addresses a critical unmet need for vascular specialists by providing automatic, real-time, accurate, numeric measurements of the flow lumen of blood vessels without the complexities of image interpretation. Provisio Medical's catheter is the world's first integrated intravascular imaging and support crossing catheter and enables vessel lumen measurement and visualization simultaneously with guidewire support and delivery of radiopaque contrast agents. 

Key Points: 
  • Groundbreaking technology for the precise, automatic measurement of peripheral blood vessels to optimize treatment strategies
    SAN DIEGO, April 25, 2024 /PRNewswire/ -- Provisio Medical today announced FDA 510(k) clearance of the Provisio™ SLT IVUS™ System.
  • Provisio Medical's catheter is the world's first integrated intravascular imaging and support crossing catheter and enables vessel lumen measurement and visualization simultaneously with guidewire support and delivery of radiopaque contrast agents.
  • The Provisio SLT IVUS System consists of the SLT IVUS™ P1 System and the SLT IVUS™ Support Crossing Catheter.
  • The SLT IVUS Support Crossing Catheter is an over-the-wire intravascular ultrasound catheter with an ultrasound transducer array at the distal end that also functions as a support crossing catheter.